Live
Endpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV successFierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma LetterFDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 YearsEndpoints NewsPharma and biotech salaries: Top-paying companies of 2025FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocusFierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization
Thermo Fisher Apr 25, 2026

Calamos Advisors LLC Raises Stake in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Calamos Advisors LLC Raises Stake in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Original
Body unavailable. Use the original source.